Concerns about PhII Parkinson gene therapy sends Neurologix into bankruptcy
This article was originally published in Scrip
Executive Summary
Neurologix Inc. filed for voluntary Chapter 7 bankruptcy protection in US Bankruptcy Court for the District of Delaware on 16 March to liquidate assets after it spent the past year looking for financing or a partner to advance its Parkinson's disease gene therapy into Phase III clinical trials.